Le Maitre Vascular, Inc. (LMAT)

Updated July 6th, 2025 by Yiannis Zourmpanos

Key Metrics

Current Price:	$84	**5 Year Annual Expected Total Return:**	11.4%	**Market Cap:**	$1.92B
Fair Value Price:	$86	**5 Year Growth Estimate:**	10.0%	**Ex-Dividend Date:**	08/15/25[1]
% Fair Value:	98%	**5 Year Valuation Multiple Estimate:**	0.4%	**Dividend Payment Date:**	08/29/25[2]
Dividend Yield:	1.0%	**5 Year Price Target**	$138	**Years Of Dividend Growth:**	14
Dividend Risk Score:	A	**Sector:**	Healthcare	**Rating:**	Buy

Overview & Current Events

LeMaitre Vascular, Inc. (LMAT) develops, markets, services, and backs medical devices and implants to treat peripheral vascular disease. Their offerings include restore flow allografts, angioscopes, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, artery graft biologic grafts, carotid shunts, radiopaque tape, valvulotomes, vascular grafts, cardiac patches, and closure systems.

On May 1st, 2025, LeMaitre announced results for the first quarter of 2025, reporting 12% sales growth to $59.9 million and non-GAAP EPS of $0.48 that missed analysts' estimates by $0.02.

LeMaitre Vascular got off to a strong start in 2025, posting organic revenue growth of 13%. The company's vascular grafts and carotid shunt product lines were standout performers, helping push EMEA sales up 18% and the Americas up 11%. Gross margin expanded modestly to 69.2% on the back of higher selling prices and better manufacturing efficiencies, while operating income rose 6% to $12.6 million despite a double-digit uptick in operating expenses tied to investments in the growing sales force. EPS climbed 10% to $0.48, and LeMaitre ended the quarter with a healthy cash position of $302.5 million, up $2.8 million sequentially, giving it plenty of strategic flexibility going forward.

Notably, Artegraft, the company's largest U.S. product, received its MDR CE Mark and will launch in Europe shortly, potentially opening new growth channels. Management also announced it will return more value to shareholders, declaring a $0.20 per share dividend while continuing its $75 million share repurchase plan. Encouraged by the Q1 momentum, LeMaitre boosted its full-year sales guidance to $245 million, up from $239 million, and lifted its organic growth outlook to 13%. All in all, the company looks poised to build on its leadership in vascular devices while maintaining its steady track record of profitable expansion.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	$0.42	$0.55	$0.86	$1.13	$0.88	$1.04	$1.25	$0.93	$1.34	$1.96	***$2.14***	***$3.45***
DPS	$0.16	$0.18	$0.22	$0.28	$0.34	$0.38	$0.44	$0.50	$0.56	$0.64	***$0.80***	***$1.61***
Shares[3]	18.3	19.2	20.0	20.2	20.3	20.5	21.5	22.2	22.4	22.8	***23.4***	***26.4***

We expect the company to post EPS of $2.14 in 2025, which is the midpoint of analysts' estimates. Also, we expect annual EPS growth of 10.0% over the next five years, leading to our estimated EPS of $3.45 by 2030. Moreover, the company has a solid record of paying dividends despite operating in a competitive healthcare sector, as LeMaitre Vascular has paid an increasing dividend for the past 14 years. Thus, we expect the company to maintain its dividend growth and have forecasted a dividend CAGR of 15.0%, leading to a dividend of $1.61 in 2030.

[1] Estimated ex-dividend date.
[2] Estimated payment date.
[3] Share count is in millions.

Le Maitre Vascular, Inc. (LMAT)

Updated July 6th, 2025 by Yiannis Zourmpanos

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	27.9	32.4	35.6	29.2	35.3	30.3	41.7	49.9	41.4	41.5	***39.3***	***40.0***
Avg. Yld.	1.4%	1.0%	0.7%	0.9%	1.1%	1.2%	0.8%	1.1%	1.0%	0.8%	***1.0%***	***1.2%***

The healthcare equipment company trades at a forward P/E of 39.3, higher than the long-term average P/E of 36.5, but lower than the five-year average P/E of 41.0. Even though the rapid sales growth will benefit the company in the near term, we assign a P/E of 40.0 to the stock, which we feel is a fair reflection of its value. Accordingly, with an EPS of $3.45 and P/E target of 40.0, our target price for the stock stands at $138 by 2030.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	38%	33%	26%	25%	39%	37%	35%	54%	42%	33%	***37%***	***47%***

The company has paid a consistent dividend to its shareholders with a 10-year payout ratio averaging 36.0%, and we expect the company to maintain and increase its payout in the future. The company's EPS has experienced a rapid increase in recent quarters, and we expect the company to be in a much better position in the future than it is today. In addition, the margins may improve aggressively in a reducing rate environment and lead to lower-rivalry niche segments. Nevertheless, a case of hard landing could adversely affect its performance. LeMaitre reinforced its commitment to shareholder returns by continuing its $75 million share repurchase program during the quarter.

Final Thoughts & Recommendation

While LeMaitre Vascular operates a competitive healthcare equipment business, a decrease in interest rates could further enhance EPS growth. Indeed, LeMaitre Vascular's dividend growth prospects could remain strong for a long time. Thus, we rate LMAT with a buy rating premised upon the 11.4% annualized total returns for the long-term, derived from the forecasted earnings-per-share growth of 10.0%, the 1.0% dividend yield, and a valuation tailwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.

Le Maitre Vascular, Inc. (LMAT)

Updated July 6th, 2025 by Yiannis Zourmpanos

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	78	89	101	106	117	129	154	162	193	220
Gross Profit	54	63	71	74	80	85	101	105	127	151
Gross Margin	69.1%	70.6%	70.1%	70.0%	68.1%	65.4%	65.7%	64.9%	65.8%	68.6%
SG&A Exp.	37	40	43	45	49	46	53	62	73	83
D&A Exp.	3	4	4	4	5	8	11	9	9.5	9.7
Operating Income	11	16	21	21	21	28	36	30	37	52
Operating Margin	14.2%	18.3%	20.9%	19.6%	18.1%	21.9%	23.6%	18.5%	19.2%	23.6%
Net Profit	8	11	17	23	18	21	27	21	30	44
Net Margin	9.9%	11.9%	17.0%	21.7%	15.3%	16.4%	17.4%	12.8%	15.5%	22.0%
Free Cash Flow	9	14	16	16	10	32	30	22	29	37
Income Tax	4	6	4	6	4	6	7	7	9.4	13

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	91	102	126	153	188	253	293	310	347	552
Cash & Equivalents	27	24	19	26	12	27	14	19	24	26
Acc. Receivable	12	13	15	16	17	20	20	22	25	30
Inventories	15	17	19	26	35	39	41	45	52	56
Goodwill & Int.	24	33	32	44	65	125	119	112	108	102
Total Liabilities	13	14	17	23	40	80	39	42	49	215
Acc. Payable	1	1	2	2	3	2	2	3	3.7	1.8
Long-Term Debt	-	-	-	-	-	38	-	-	-	168
Total Equity	78	88	110	130	148	173	254	268	298	337
LTD/E Ratio	-	-	-	-	-	0.22	-	-	-	0.50

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	9.0%	11.0%	15.1%	16.4%	10.5%	9.6%	9.9%	6.8%	9.2%	9.8%
Return on Equity	10.6%	12.8%	17.4%	19.1%	12.9%	13.2%	12.6%	7.9%	10.6%	13.9%
ROIC	10.6%	12.8%	17.4%	19.1%	12.9%	11.8%	11.6%	7.9%	10.6%	11.0%
Shares Out.	18.3	19.2	20.0	20.2	20.3	20.5	21.5	22.2	22.4	22.8
Revenue/Share	4.28	4.63	5.04	5.22	5.77	6.32	7.19	7.29	8.63	9.65
FCF/Share	0.50	0.73	0.82	0.81	0.51	1.55	1.41	1.00	1.32	1.63

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.